该试验正在测试HT-001,这是一种用于治疗EGFR抑制剂癌症疗法引起的皮肤毒性的药物。据估计,每年约有20万美国人开始接受EGFR抑制剂癌症疗法,其中多达三分之一的患者会出现严重的皮肤反应,可能导致剂量减少或治疗中断。目前尚无FDA批准的治疗方法用于这种病症。

(RTTNews) - Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT. The study focuses on: development and optimization ...

Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism. Processing and qualitative evaluation of tissue samples by a board-certified ...

Positive EU regulatory conclusion achieved Oncology-focused clinical program Multi-country European trial footprint Clear line of sight to site activation and enrollment Near-term regulatory and ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at ...

The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR ...

Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any ...